Literature DB >> 1513919

Debrisoquine hydroxylation phenotyping in geriatric psychopharmacology.

B G Pollock1, J M Perel, L P Altieri, M Kirshner, A L Fasiczka, P R Houck, C F Reynolds.   

Abstract

The metabolic ratios (MRs) between debrisoquine (DBQ) and 4-hydroxydebrisoquine in urine after a single dose of 10 mg DBQ was determined in 175 unmedicated, healthy subjects older than age 59 (mean of 75 years). Creatinine clearance was determined on the same 8-hour urine collection. Test procedures were well tolerated in all cases. Although age was significantly correlated with creatinine clearance (r = -.38), there was no relationship between age and MR. Analysis by kernel density estimation revealed a bimodal distribution of MRs with an antimode of 11.6. Six subjects (3.4%) were categorically slow DBQ metabolizers (MR greater than 11.6). The proportion of elderly slow metabolizers approaches the lower range determined in a younger population. Our findings, that DBQ oxidative metabolism does not necessarily change with aging, alone, and that (genetic) slow DBQ metabolizers endure into old age, remaining at risk for treatment with many commonly used psychotropics, suggests the need to study the relevance of metabolic phenotyping in elderly psychiatric patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1513919

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  12 in total

Review 1.  Drug metabolism and ageing.

Authors:  M T Kinirons; M S O'Mahony
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

Review 2.  Polymorphic cytochromes P450 and drugs used in psychiatry.

Authors:  R T Coutts; L J Urichuk
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 3.  New atypical antipsychotics. Experience and utility in the elderly.

Authors:  R A Sweet; B G Pollock
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923

4.  Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism.

Authors:  Kosuke Doki; Masato Homma; Keisuke Kuga; Kazutaka Aonuma; Yukinao Kohda
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

Review 5.  Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?

Authors:  V Ozdemir; J Fourie; U Busto; C A Naranjo
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

Review 6.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 7.  Paroxetine. A review of its pharmacology, therapeutic use in depression and therapeutic potential in diabetic neuropathy.

Authors:  S M Holliday; G L Plosker
Journal:  Drugs Aging       Date:  1993 May-Jun       Impact factor: 3.923

Review 8.  Metabolism of tricyclic antidepressants.

Authors:  M V Rudorfer; W Z Potter
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

Review 9.  Antipsychotics in older patients. A safety perspective.

Authors:  B G Pollock; B H Mulsant
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

10.  Effect of gender and age on the pharmacokinetics of repinotan.

Authors:  Roland Heinig; Pavur Sundaresan; Anita Shah; Michael Boettcher
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.